INOmax

In the US, INOmax (nitric oxide systemic) is a member of the drug class miscellaneous respiratory agents and is used to treat Respiratory Failure.

US matches:

• INOmax inhalation gas


• INOmax

Ingredient matches for INOmax

Nitric Oxide

Nitric oxide is reported as an ingredient of INOmax in the following countries:

• Australia


• Czech Republic


• Denmark


• France


• Germany


• Greece


• Italy


• Luxembourg


• Slovakia


• Spain


• Sweden


• Switzerland


• United States

International Drug Name Search

Mebendazol L.CH.

Mebendazol L.CH. may be available in the countries listed below.

Ingredient matches for Mebendazol L.CH.

Mebendazole

Mebendazole is reported as an ingredient of Mebendazol L.CH. in the following countries:

• Chile

International Drug Name Search

Strep Sol

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Strep Sol

Streptomycin

Streptomycin sulfate (a derivative of Streptomycin) is reported as an ingredient of Strep Sol in the following countries:

• United States

International Drug Name Search

Verapamil Pliva

Verapamil Pliva may be available in the countries listed below.

Ingredient matches for Verapamil Pliva

Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Verapamil Pliva in the following countries:

• Italy

International Drug Name Search

Venlafaxin Ranbaxy

Venlafaxin Ranbaxy may be available in the countries listed below.

Ingredient matches for Venlafaxin Ranbaxy

Venlafaxine

Venlafaxine is reported as an ingredient of Venlafaxin Ranbaxy in the following countries:

• Austria

International Drug Name Search

Idrolax

Idrolax may be available in the countries listed below.

Ingredient matches for Idrolax

Macrogol

Macrogol 4000 (a derivative of Macrogol) is reported as an ingredient of Idrolax in the following countries:

• United Kingdom

International Drug Name Search

Vagantyl

Vagantyl may be available in the countries listed below.

Ingredient matches for Vagantyl

Mosapride

Mosapride citrate dihydrate (a derivative of Mosapride) is reported as an ingredient of Vagantyl in the following countries:

• Argentina

International Drug Name Search

Hofcomant

Hofcomant may be available in the countries listed below.

Ingredient matches for Hofcomant

Amantadine

Amantadine sulfate (a derivative of Amantadine) is reported as an ingredient of Hofcomant in the following countries:

• Austria


• Greece

International Drug Name Search

Telfin

Telfin may be available in the countries listed below.

Ingredient matches for Telfin

Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Telfin in the following countries:

• Bangladesh

International Drug Name Search

Dipyridamol Actavis

Dipyridamol Actavis may be available in the countries listed below.

Ingredient matches for Dipyridamol Actavis

Dipyridamole

Dipyridamole is reported as an ingredient of Dipyridamol Actavis in the following countries:

• Netherlands

International Drug Name Search

Vétranquil

Vétranquil may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vétranquil

Acepromazine

Acepromazine maleate (a derivative of Acepromazine) is reported as an ingredient of Vétranquil in the following countries:

• France

International Drug Name Search

Timentin

In the US, Timentin (clavulanate/ticarcillin systemic) is a member of the drug class beta-lactamase inhibitors and is used to treat Aspiration Pneumonia, Bacteremia, Bacterial Infection, Bone infection, Deep Neck Infection, Endometritis, Febrile Neutropenia, Intraabdominal Infection, Joint Infection, Kidney Infections, Pelvic Inflammatory Disease, Peritonitis, Pneumonia, Pneumonia with Cystic Fibrosis, Septicemia, Skin Infection and Urinary Tract Infection.

US matches:

• Timentin


• Timentin injection


• Timentin Novaplus

UK matches:

• Timentin 0.8 G, 1.6 G, 3.2 G (SPC)

Ingredient matches for Timentin

Clavulanate

Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Timentin in the following countries:

• Australia


• Bahrain


• Belgium


• Brazil


• Canada


• Czech Republic


• Greece


• Hong Kong


• India


• Iran


• Israel


• Italy


• Kuwait


• Luxembourg


• New Zealand


• Oman


• Philippines


• Poland


• Qatar


• Romania


• Russian Federation


• Sri Lanka


• Taiwan


• United Arab Emirates


• United Kingdom


• United States

Ticarcillin

Ticarcillin disodium salt (a derivative of Ticarcillin) is reported as an ingredient of Timentin in the following countries:

• Australia


• Bahrain


• Belgium


• Brazil


• Canada


• Czech Republic


• Greece


• Hong Kong


• India


• Iran


• Israel


• Italy


• Kuwait


• Luxembourg


• New Zealand


• Oman


• Philippines


• Poland


• Qatar


• Romania


• Russian Federation


• Sri Lanka


• Taiwan


• United Arab Emirates


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Reclast

Reclast is a brand name of zoledronic acid, approved by the FDA in the following formulation(s):

RECLAST (zoledronic acid - injectable; iv (infusion))

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 16, 2007
  
  Strength(s): EQ 5MG BASE/100ML ^[RLD]

Has a generic version of Reclast been approved?

No. There is currently no therapeutically equivalent version of Reclast available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reclast. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted alkanediphosphonic acids and pharmaceutical use
  Patent 4,939,130
  Issued: July 3, 1990
  Inventor(s): Jaeggi; Knut A. & Widler; Leo
  Assignee(s): Ciba-Geigy Corporation
  Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.
  
  Patent expiration dates:
  
  
  • September 2, 2012
    
    ✓ 
    Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 2, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical products comprising bisphosphonates
  Patent 7,932,241
  Issued: April 26, 2011
  Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
  Assignee(s): Novartis AG
  A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
  
  Patent expiration dates:
  
  
  • February 5, 2028
    
    ✓ 
    Drug product
  
  
  
  • August 5, 2028
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of administering bisphosphonates
  Patent 8,052,987
  Issued: November 8, 2011
  Inventor(s): Horowitz; Zebulun D. & Richardson; Peter C. & Trechsel; Ulrich
  Assignee(s): Novartis Pharmaceuticals Corporation
  The invention relates to bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, and to methods of treatment using bisphosphonates. These bisphosphonates are used with satisfactory results for prolonged inhibition of bone resorption in conditions of abnormally increased bone turnover, e.g. osteoporosis, by intermittent administration, the periods between bisphosphonate administrations are longer than was previously considered appropriate, e.g. a dosing interval of at least about 6 months or less frequently.
  
  Patent expiration dates:
  
  
  • March 19, 2024
    
    ✓ 
    Patent use: TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 17, 2010 - TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  
  
  • October 16, 2010 - PEDIATRIC EXCLUSIVITY
  
  
  • February 17, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • December 19, 2011 - TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
  
  
  • March 15, 2012 - TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
  
  
  • May 29, 2012 - PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  
  

See also...

• Reclast Consumer Information (Drugs.com)
• Reclast Consumer Information (Wolters Kluwer)
• Reclast Consumer Information (Cerner Multum)
• Reclast Advanced Consumer Information (Micromedex)
• Zoledronic Acid Consumer Information (Wolters Kluwer)
• Zoledronic acid Consumer Information (Cerner Multum)
• Zoledronic acid Intravenous Advanced Consumer Information (Micromedex)
• Zoledronic Acid AHFS DI Monographs (ASHP)

Vitamine A

Vitamine A may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vitamine A

Retinol

Retinol is reported as an ingredient of Vitamine A in the following countries:

• Tunisia

Retinol propionate (a derivative of Retinol) is reported as an ingredient of Vitamine A in the following countries:

• Netherlands

International Drug Name Search

Cefalotina Richmond

Cefalotina Richmond may be available in the countries listed below.

Ingredient matches for Cefalotina Richmond

Cefalotin

Cefalotin sodium salt (a derivative of Cefalotin) is reported as an ingredient of Cefalotina Richmond in the following countries:

• Argentina

International Drug Name Search

Amdocal

Amdocal may be available in the countries listed below.

Ingredient matches for Amdocal

Amlodipine

Amlodipine is reported as an ingredient of Amdocal in the following countries:

• Bangladesh

International Drug Name Search

Vasorel

Vasorel may be available in the countries listed below.

Ingredient matches for Vasorel

Trimetazidine

Trimetazidine dihydrochloride (a derivative of Trimetazidine) is reported as an ingredient of Vasorel in the following countries:

• China

International Drug Name Search

Robinul

See also: Generic Robinul Forte

Robinul is a brand name of glycopyrrolate, approved by the FDA in the following formulation(s):

ROBINUL (glycopyrrolate - injectable; injection)

• 
  Manufacturer: BAXTER HLTHCARE
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 0.2MG/ML ^[RLD][AP]

ROBINUL (glycopyrrolate - tablet; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 1MG ^[RLD][AA]

Has a generic version of Robinul been approved?

A generic version of Robinul has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Robinul and have been approved by the FDA:

glycopyrrolate injectable; injection

• 
  Manufacturer: HIKMA FARMACEUTICA
  
  Approval date: September 21, 2011
  
  Strength(s): 0.2MG/ML ^[AP]


• 
  Manufacturer: LUITPOLD
  
  Approval date: July 23, 1986
  
  Strength(s): 0.2MG/ML ^[AP]

glycopyrrolate tablet; oral

• 
  Manufacturer: BOCA PHARMA
  
  Approval date: October 19, 2011
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: COREPHARMA
  
  Approval date: December 22, 2004
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: March 21, 2008
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: PAR PHARM
  
  Approval date: August 31, 2006
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: RANBAXY
  
  Approval date: August 18, 2009
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: VINTAGE
  
  Approval date: December 29, 2008
  
  Strength(s): 1MG ^[AA]


• 
  Manufacturer: WEST WARD
  
  Approval date: March 5, 2009
  
  Strength(s): 1MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Robinul. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of glycopyrrolate
  Patent 7,091,236
  Issued: August 15, 2006
  Inventor(s): Roberts; Alan & Venkataraman; Bala
  Assignee(s): Sciele Pharma, Inc.
  The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food.
  
  Patent expiration dates:
  
  
  • April 24, 2024
    
    ✓ 
    Patent use: FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
  
  

See also...

• Robinul Consumer Information (Wolters Kluwer)
• Robinul Tablets Consumer Information (Wolters Kluwer)
• Robinul Consumer Information (Cerner Multum)
• Robinul Advanced Consumer Information (Micromedex)
• Robinul AHFS DI Monographs (ASHP)
• Glycopyrrolate Consumer Information (Wolters Kluwer)
• Glycopyrrolate Solution Consumer Information (Wolters Kluwer)
• Glycopyrrolate Tablets Consumer Information (Wolters Kluwer)
• Glycopyrrolate Consumer Information (Cerner Multum)
• Glycopyrrolate Advanced Consumer Information (Micromedex)
• Glycopyrrolate AHFS DI Monographs (ASHP)

Vet-Ketofen

Vet-Ketofen may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vet-Ketofen

Ketoprofen

Ketoprofen is reported as an ingredient of Vet-Ketofen in the following countries:

• Italy

International Drug Name Search